Worldwide Clinical Trials | Oncology

Executing Bladder Cancer Trials in a Complex Clinical Landscape

Bladder cancer is a key area of expertise for Worldwide Clinical Trials, with experience spanning early-phase proof-of-concept studies, pivotal Phase III registration trials, and large observational studies across immuno-oncology (IO), targeted therapies, and oncolytic virus modalities.

The successful delivery of bladder cancer studies requires specialized knowledge of catheter-based drug administration, the operational challenges associated with BCG supply limitations, and the management of recurrence-driven efficacy endpoints. Partnering with an oncology-focused CRO that understands these complexities is critical to trial success.

Robust pipeline of bladder cancer trials

Global Footprint

- Programs across North America, Europe, Asia-Pacific, Latin America, and the Middle East and North Africa

Study Experience

- 15+ early and late phase studies with 3,400+ patients
- Real-world data, 2000+ patient registry study
- One Biological License Application in 2026

Site Experience

- 250+ investigative sites

Next-generation drug modalities

- Antibody-drug conjugates (ADCs)
- Multi/bi-specific antibodies
- Cell therapies/CAR T
- Small molecule inhibitors
- Oncolytic viruses
- Vaccines

We understand bladder cancer trials

Specialized site partnerships

- Community and large urology group practice associations
- Society of Urologic Oncology networks

Operational challenges

- Intravesical therapy administration and catheter-based procedures
- BCG supply chain shortages
- Procedure-related adverse events

Key study endpoints

- Recurrence-free survival, disease-free survival, event-free survival
- Secondary outcomes: reduced cystoscopy or need for transurethral resection of bladder tumor (TURBT)

15+
Bladder Cancer Studies

3,400+
Patients Enrolled

250+
Investigative Sites

Global Footprint
NA, EU, APAC, LATAM, MENA

What Sets Us Apart

Biotech Mindset Delivered Worldwide

We are purpose built around a biotech mindset that shapes both our partnership philosophy and delivery model, bringing the agility, responsiveness, and focus needed to meet critical oncology development milestones.

Oncology Expertise and Team Continuity

Oncology expertise is embedded across all functions, ensuring studies are led by professionals who understand the complexities of oncology science and trial execution. With an average of 11+ years of oncology experience across key roles and an industry-leading 90%+ retention rate in the oncology business unit, you can expect a seasoned, specialized team supporting your study end to end.

Flexible solutions & best-in-class technologies

Data-centric approach with visual analytics & clinical science

Site relationships with rapid startup

Global footprint: 4,000+ across NA, EU, LATAM, MENA & APAC

Active Next-Gen Oncology Experience

Operating both locally and globally across Phases I through III in a range of solid tumor and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge modalities.

Phase



Early Phase · Late Phase · Observational/LTFU

Indication



Solid · Heme

Drug Class



Immuno-Oncology · Other · Targeted Therapy

Worldwide Clinical Trials

Oncology at Worldwide

Worldwide features a dedicated oncology business unit within our full-service global contract research organization. We partner with biopharmaceutical sponsors to deliver expert-led, globally scalable oncology trials across every phase of development. We help sponsors move fast with confidence and scale without disruption.

Contact us to learn how we can support your oncology program from FIH through registration.